Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 529

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor

Maira, Sauveur-Michel, Pecchi, Sabina, Huang, Alan, Burger, Matthew, Knapp, Mark, Sterker, Dario, Schnell, Christian, Guthy, Daniel, Nagel, Tobi, Wiesmann, Marion, Brachmann, Saskia, Fritsch, Christine, Dorsch, Marion, Chène, Patrick, Shoemaker, Kevin, De Pover, Alain, Menezes, Daniel, Martiny-Baron, Georg, Fabbro, Doriano, Wilson, Christopher J., Schlegel, Robert, Hofmann, Francesco, García-Echeverría, Carlos, Sellers, William R., Voliva, Charles F.·2012·Molecular Cancer Therapeutics

Abstract

Following the discovery of NVP-BEZ235, our first dual pan-PI3K/mTOR clinical compound, we sought to identify additional phosphoinositide 3-kinase (PI3K) inhibitors from different chemical classes with a different selectivity profile. The key to achieve these objectives was to couple a structure-based design approach with intensive pharmacologic evaluation of selected compounds during the medicinal chemistry optimization process. Here, we report on the biologic characterization of the 2-morpholino pyrimidine derivative pan-PI3K inhibitor NVP-BKM120. This compound inhibits all four class I PI3K isoforms in biochemical assays with at least 50-fold selectivity against other protein kinases. The compound is also active against the most common somatic PI3Kα mutations but does not significantly inhibit the related class III (Vps34) and class IV (mTOR, DNA-PK) PI3K kinases. Consistent with its mechanism of action, NVP-BKM120 decreases the cellular levels of p-Akt in mechanistic models and relevant tumor cell lines, as well as downstream effectors in a concentration-dependent and pathway-specific manner. Tested in a panel of 353 cell lines, NVP-BKM120 exhibited preferential inhibition of tumor cells bearing PIK3CA mutations, in contrast to either KRAS or PTEN mutant models. NVP-BKM120 shows dose-dependent in vivo pharmacodynamic activity as measured by significant inhibition of p-Akt and tumor growth inhibition in mechanistic xenograft models. NVP-BKM120 behaves synergistically when combined with either targeted agents such as MEK or HER2 inhibitors or with cytotoxic agents such as docetaxel or temozolomide. The pharmacological, biologic, and preclinical safety profile of NVP-BKM120 supports its clinical development and the compound is undergoing phase II clinical trials in patients with cancer. Mol Cancer Ther; 11(2); 317–28. ©2011 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-11-0474

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Cited by

See all 529

Metadata

Authors
Maira, S.-M., Pecchi, S., Huang, A., Burger, M., Knapp, M., Sterker, D., Schnell, C., Guthy, D., Nagel, T., Wiesmann, M., Brachmann, S., Fritsch, C., Dorsch, M., Chène, P., Shoemaker, K., De Pover, A., Menezes, D., Martiny-Baron, G., Fabbro, D., Wilson, C. J., Schlegel, R., Hofmann, F., García-Echeverría, C., Sellers, W. R., & Voliva, C. F.
Venue
Molecular Cancer Therapeutics
Published
2012-02-01
Volume
11
Issue
2
Pages
317-328
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2154871907
Cited by
529
References
41
FWCI
16.46
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor. https://app.cochat.ai/papers/10.1158/1535-7163.mct-11-0474
The paper
Maira, S.-M., Pecchi, S., Huang, A., Burger, M., Knapp, M., Sterker, D., Schnell, C., Guthy, D., Nagel, T., Wiesmann, M., Brachmann, S., Fritsch, C., Dorsch, M., Chène, P., Shoemaker, K., De Pover, A., Menezes, D., Martiny-Baron, G., Fabbro, D., . . . Voliva, C. F. (2012). Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-11-0474

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.